Grazia joined King’s College London in September 2023 with a post-doctoral clinical fellowship supported by Guarantors of Brain (https://guarantorsofbrain.org/brain-fellows/dr-grazai-rutigliano/). Her current work focusses on translational psychiatry and psychopharmacology. She investigates novel antipsychotic drugs using animal models and neuroimaging in clinical trials. Grazia graduated from Sant’Anna School of Advanced Studies as Doctor of Medicine and PhD in Translational Medicine. She trained as Psychiatrist at the University of Pisa. From 2021 to 2023 she was supported by the European Union’s Horizon 2020 program under the Marie Skłodowska-Curie grant and was based at Imperial College London/MRC London Institute of Medical Sciences, Psychiatric Imaging Research Group (https://lms.mrc.ac.uk/research-group/psychiatric-imaging/). Her publications feature articles on the clinical high-risk state for psychosis and trace amine-associated receptors.  

 

Research Interests: 

• Psychosis
• Translational Psychiatry
• Psychopharmacology
• Trace Amine-Associated Receptors
• Psychiatric Imaging

 

Research Groups: 

 Psychiatric Imaging Group, led by Prof Oliver Howes

 

Orchid ID:

https://orcid.org/0000-0001-6014-5357

 

Expertise and Public Engagement: 

Grazia regularly participates in societal engagement activities targeting young people, patients with psychosis and their carers. She designed and presented the activity “Who ordered pizza with extra dopamine?” within Science is Wonderful! (2021), an outreach activity organized by the European Commission (https://www.scienceiswonderful.eu/v), and the Great Exhibition Road Festival (2023), an event organized by Imperial College London and delivered in collaboration with the Royal Albert Hall, the Science Museum, NHM, V&A, the Royal Colleges of Art and Music and many others (https://www.greatexhibitionroadfestival.co.uk/event/who-ordered-pizza-extra-dopamine/). She serves as Editorial Board Member for several International Indexed Journals. 

 

key publications: 

Halff, E.F., Rutigliano, G., Garcia-Hidalgo, A., Howes, O.D. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends in Neurosciences, 2023, 46(1), pp. 60–74.

 

Rutigliano, G., Bräunig, J., Del Grande, C., ... Biebermann, H., Zucchi, R. Non-functional trace amine-associated receptor 1 variants in patients with mental disorders. Frontiers in Pharmacology, 2019, 10, 1027.

 

Accorroni, A., Rutigliano, G., Sabatini, M., ...Zucchi, R., Origlia, N. Exogenous 3-Iodothyronamine Rescues the Entorhinal Cortex from β-Amyloid Toxicity. Thyroid, 2020, 30(1), pp. 147–160.

 

Rutigliano, G., Accorroni, A., Zucchi, R. The case for TAAR1 as a modulator of central nervous system function. Frontiers in Pharmacology, 2018, 8(JAN), 987.

 

Rutigliano, G., Merlino, S., Minichino, A., ... McGuire, P., Fusar-Poli, P. Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. European Psychiatry, 2018, 52, pp. 126–133.

 

Fusar-Poli, P., Rutigliano, G., Stahl, D., ...Reilly, T., McGuire, P. Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis. JAMA Psychiatry, 2017, 74(5), pp. 493–500.

 

Fusar-Poli, P., Rutigliano, G., Stahl, D., ... Hitesh, S., McGuire, P. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry, 2016, 73(12), pp. 1260–1267.

 

Rutigliano, G., Valmaggia, L., Landi, P., ...McGuire, P., Fusar-Poli, P. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. Journal of Affective Disorders, 2016, 203, pp. 101–110.